Summary of COVID-19 vaccine-related erythema multiforme at Kindai University Hospital, Japan

Keiko Watanabe, Chisa Nakashima, Ayako Matsuo, Maiko Kato, Shigeto Yanagihara, Naoki Oiso, Atsushi Otsuka

Article ID: 1653
Vol 6, Issue 2, 2022

VIEWS - 593 (Abstract) 228 (PDF)


The recently extended use of mRNA vaccines due to the COVID-19 pandemic has allowed the description of multiple cutaneous adverse events including local injection site reactions, urticaria, and morbilliform eruptions. COVID-19 vaccine-related cutaneous reaction patterns can be divided into type Ⅰ hypersensitivity reactions, type Ⅳ hypersensitivity reactions, autoimmune-related, and functional angiopathies based on pathogenesis. Erythema multiforme (EM), a type IV hypersensitivity reaction, has also been reported from several centers. We experienced the remarkable improvement of COVID-19 vaccine-related EM with systemic administration of prednisolone and summarized six cases experienced in our department.


COVID-19; Erythema Multiforme Vaccination

Full Text:



1. Gambichler T, Boms S, Susok L, et al. Cutaneous findings following COVID-19 vaccination: Review of world literature and own experience. Journal of the European Academy of Dermatology and Venereology 2022; 36(2): 172–180. doi: 10.1111/jdv.17744.

2. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. Journal of the American Academy of Dermatology 2021; 85(1): 46–55. doi: 10.1016/j.jaad.2021.03.092.

3. Grieco T, Maddalena P, Sernicola A, et al. Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study. Dermatologic Therapy 2021; 34(6): e15153. doi: 10.1111/dth.15153.



  • There are currently no refbacks.

Copyright (c) 2022 Chisa Nakashima, Keiko Watanabe, Ayako Matsuo, Maiko Kato, Shigeto Yanagihara, Naoki Oiso, Atsushi Otsuka

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This site is licensed under a Creative Commons Attribution 4.0 International License.